Skip to main content

Table 1 Gliptins summarized data on approving authority, pharmacokinetics, chemistry, half life, dosage and catabolic pathway

From: Antidiabetic treatment with gliptins: focus on cardiovascular effects and outcomes

Compound

Approval

Peptidomimetic

Chemistry

Maximal half life, hours

Usual dose, mg

Main catabolic pathway

Alogliptin

FDA, 2013

–

Pyrimidinedione

<21

25 qd

Renal

Anagliptin

Japan, 2012

+

Cyanopyrrolidine

<4.5a

100 bid

Renal

Linagliptin

FDA, 2011

–

Xanthine

<40

5 qd

Biliary

Saxagliptin

FDA, 2009

+

Cyanopyrrolidine

<4b

5 qd

Renal

Sitagliptin

FDA, 2006

–

Beta-amino acid

<24

100 qd

Renal

Teneligliptin

Japan, 2012

+

Prolylthiazolidine

<24

20 qd

Renal

Vildagliptin

European Union, 2007

+

Cyanopyrrolidine

<4.5

50 bid

Renal

  1. aIn addition, <10 h of partially active metabolite
  2. bIn addition, <7 h of partially active metabolite